Barbara Burtness, MD

Articles

Clinical Scenario: Metastatic EBV-Positive NPC

September 25th 2024

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Clinical Scenario: Locally Recurrent NPC

September 18th 2024

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

September 18th 2024

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

September 11th 2024

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

September 11th 2024

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

September 4th 2024

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

September 4th 2024

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Value of PD-L1 Biomarker in NPC

August 28th 2024

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Overview of the JUPITER and POLARIS-2 Trials

August 28th 2024

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

Current Guidelines for Managing Nasopharyngeal Carcinoma

August 21st 2024

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

August 21st 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Dr Burtness on Subgroup Outcomes for Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

June 14th 2024

Barbara Burtness, MD, discusses findings from a subgroup analysis from the phase 2 E3311 trial in HPV-associated oropharynx cancer.

Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 3rd 2023

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.

Dr. Burtness on the Efficacy of Checkpoint Inhibitors in Head & Neck Cancer

June 29th 2021

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Dr. Burtness on the Effectiveness of Immunotherapy in Head and Neck Cancers

March 31st 2020

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Dr. Burtness on the Future of Immunotherapy in Head and Neck Cancer

August 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the future of immunotherapy in head and neck cancer.

Dr. Burtness on the Use of Biomarkers in Metastatic HNSCC

April 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

Dr. Burtness on Promise of Frontline Pembrolizumab in Metastatic HNSCC

March 30th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.

Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer

December 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Burtness on Frontline Immunotherapy in Head and Neck Cancer

November 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses frontline immunotherapy in head and neck cancer.